Genticel announces positive data from its phase I trial in women infected with high-risk HPV before appearance of cervical lesions
Paris, France, October 18, 2012 – Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), today announces positive safety and immunogenicity data obtained in the phase I study with its lead product ProCervix, a vaccine designed to induce a curative cellular immune response in patients infected with HPV16 and/or HPV18. These high-risk human papillomavirus (HPV) types are responsible for respectively 50 per cent and 20 per cent of cervical cancer world-wide.
ProCervix is targeted at women who are already infected by the HPV16 and/or HPV18 virus types before high grade lesions or cancer occurs. It is the first vaccine to address the medical need of this high risk population as the preventive HPV vaccines are aimed at protecting people who are not infected.
The clinical trial is conducted at the Centre for the Evaluation of Vaccinations in the Vaccine and Infectious Disease Institute of the University of Antwerp, Belgium. The study is directed by Professor Pierre Van Damme. The key objectives of the trial are to evaluate the safety and immunogenicity of ProCervix in combination with a commercially available product as adjuvant. The trial includes ascending dose cohorts as well as a placebo-controlled, double-blind, randomized extension.
The data indicate that ProCervix plus adjuvant shows good safety and local tolerance at the highest dose evaluated. HPV-E7- antigen specific T cell responses have been detected in a majority of vaccinated women. Moreover, viral clearance is several-fold higher in the group of patients treated with ProCervix than in the placebo group.
"This Phase I trial with ProCervix has met both its primary objective (safety and local tolerance) and secondary objective (antigen-specific cellular immunity)," said Dr. Benedikt Timmerman, chief executive officer of Genticel. "In addition, the results available suggest that ProCervix with adjuvant is clearing the virus in HPV16- or HPV18- infected women."
"This trial is the first ever to recruit HPV infected women with no cervical lesions; ProCervix may become the first product that actually closes the gap between preventive vaccines and later stage therapeutic options," said Dr Marie-Christine Bissery, chief scientific officer of Genticel. "Additional longer-term clinical data is being collected, including viral clearance in women vaccinated with a reconstituted lyophilized form of ProCervix."
About the technology
ProCervix uses the Adenylate Cyclase (CyaA) technology, a protein vector delivering the E7 antigens from HPV16 and HPV18. The CyaA vector directly targets professional antigen presenting cells (APC) in vivo. Through its unique delivery mode, CyaA allows the antigen to induce strong CD4+ and CD8+ T cell responses. ProCervix is the first HPV vaccine to leverage the CyaA's mode of action.
About the Human Papillomavirus (HPV) and cervical cancer
Recent estimates by the World Health Organization suggest that world-wide approximately 300 million women are carriers of HPV at any given time. Of these, about 93 million women are infected with HPV16 and/or HPV18 types, of this population approximately 350,000 patients are diagnosed with cervical cancer each year.
About Genticel S.A.
GENTICEL is a clinical stage biopharmaceutical company based in Paris and Toulouse, France, which develops vaccines for patients infected with Human Papillomavirus (HPV). Besides ProCervix, its other pipeline products include CyaA-based multivalent HPV vaccines with additional virus subtype coverage. For more information, please visit http://www.genticel.com
ANDREW LLOYD & ASSOCIATES
Follow us on Twitter: https://twitter.com/ALA_Group
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION